je.st
news
GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing
2014-03-05 04:40:25| drugdiscoveryonline Home Page
GE Healthcare recently announced that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation (FISH) technologies to improve virtual analysis of testing results for a variety of blood diseases, including leukemia, lymphoma, myelodysplastic syndrome and myeloma
Tags: technologies
testing
fish
healthcare
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||